CAMBRIDGE COGNITION HOLDINGS PLC – Result Of Retail Offer
RNS Number : 2645K Cambridge Cognition Holdings PLC 30 June 2026 30 June 2026 Cambridge Cognition Holdings plc
RNS Number : 2645K Cambridge Cognition Holdings PLC 30 June 2026 30 June 2026 Cambridge Cognition Holdings plc
RNS Number : 4646J Cambridge Cognition Holdings PLC 24 June 2026 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR
Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce further contract wins in the first half of 2020, taking the order intake to £4.9m for the year to date, compared with £2.6m for the first half of 2019.
Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, announces its unaudited Interim Results for the six months ended 30 June 2019.
Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, announces a trading update ahead of the release of the Company’s interim results for the six months to 30 June 2019 (“H1 2019”), which will be released on 19 September 2019.
Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce the second commercial partnership with a leading pharmaceutical company, for its NeuroVocalixTM platform.
The neuroscience technology company, Cambridge Cognition Holdings plc (AIM: COG), which develops and markets neuroscience technologies to assess brain health, is pleased to announce the appointment of Debra Leeves as a Non-Executive Director with immediate effect.
The neuroscience technology company Cambridge Cognition Holdings plc (AIM: COG), which develops and markets neuroscience technologies to assess brain health, today announces a significant new contract providing digital health technologies to a major pharmaceutical company for application in a clinical stage development programme.
Cambridge Cognition Holdings plc, which develops and markets neuroscience technology to assess brain health, is pleased to announce that Dr. Matthew Stork has agreed to join the Company as Chief Operating Officer on completion of the fundraise announced earlier today.
Cambridge Cognition Holdings plc, which develops and markets neuroscience technology to assess brain health, today announcesits preliminary results for the year ended 31 December 2018.